ArticleBioactive materials2026
Sprayable lipid-based lubricated hydrogel coating for alleviating catheter-related mucosal damage and pain.
Article in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medical catheters are essential for clinical diagnosis and therapy, yet their insertion and retention inevitably cause mucosal damage and pain. Conventional catheters compromise comfort and risk secondary inflammation, underscoring the need for advanced catheter surface coatings. Herein, we developed a sprayable lipid-based lubricated hydrogel coating (Oxy@Lipo/Gel) by integrating oxybuprocaine-loaded liposomes (Oxy@Lipo) with an oxidized hyaluronic acid/carboxymethyl chitosan (OHA/CMCS) hydrogel. The OHA/CMCS hydrogel enables rapid spray-induced gelation, while Oxy@Lipo acts as a carrier for the local anesthetic oxybuprocaine. Oxy@Lipo/Gel not only enhances catheter hydrophilicity, reduces interfacial friction and nonspecific protein adsorption, but also exhibits pH-responsive drug release, self-healing capacity, and appropriate degradability. It is worth noting that Lipo dramatically augments the hydrogel's lubricity by reconstruction of phospholipid lubricating interface upon friction-induced migration and surface exposure of Lipo. Furthermore, Oxy@Lipo/Gel-coated endotracheal tube significantly minimize intubation-induced heart rate fluctuations of rhesus monkey, alleviate airway mucosal injury and pain responses effectively, and preserve post-extubation feeding willingness. Mechanistically, Oxy@Lipo/Gel mitigates mucosal damage and pain by activating the Nrf2 pathway for antioxidant defense, inhibiting the pro-inflammatory MAPK cascade, and facilitating M2 macrophage polarization. Collectively, Oxy@Lipo/Gel emerges as a promising strategy to mitigate catheter-related mucosal damage and pain, holding substantial potential for clinical translation and application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.